A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Have other known disease-causing mutations documented in the subject's medical history or identified through a retinal dystrophy gene panel, that in the opinion of the investigator would interfere with the potential therapeutic effect of the study agent or the quality of the assessments.

For subjects with herpes simplex virus (HSV):

1. Have history of oral or genital herpes and unable and/or unwilling to utilize prophylactic antiviral medication.

2. Have a history of ocular herpes.

3. Have active oral or genital herpes or are currently receiving treatment for HSV infection.

Have complicating systemic diseases (e.g., medical conditions causing immunosuppression, active systemic infection) that would preclude the gene transfer or ocular surgery.

Have known sensitivity or allergy to systemic corticosteroids or other immunosuppressive medications.

Have used anti-coagulant agents that may alter coagulation

Have received any vaccination/immunization within 28 days prior to screening and/or during screening with the exception of the influenza vaccine, which is only exclusionary if they have received the influenza vaccine within 28 days prior to randomization.

Have used systemic corticosteroids or other immunosuppressive medications within 3 months prior to screening and/or intend to use during screening.

Have previously received any AAV gene therapy product, stem cell therapy, cell-based therapy, or similar biologics.

Have pre-existing eye conditions that would preclude the planned surgery, interfere with the interpretation of study endpoints, or increase the risk of surgical complications

Have significant media opacity impacting evaluation of the retina or vitreous.

Had intraocular surgery within 90 days of study treatment administration.

Have any active ocular/intraocular infection or inflammation

Have a history of steroid-induced raised IOP of \>25 mmHg following corticosteroid exposure, despite topical IOP-lowering pharmacologic therapy.

Have any artificial retinal implant or prosthesis.

Have absence of clear ocular media and/or inadequate pupil dilation to facilitate good quality OCT images.

Have any history of rhegmatogenous retinal detachment.

Have myopia (spherical equivalent) exceeding -10 diopters (or axial length of \>30 mm if PI deems it appropriate to measure) or presence of pathologic myopia in the study eye.

Have passed the Low Contrast Ora-VNC™ mobility course in either eye or binocularly at any screening visit.

What this study is about